US Bancorp DE Acquires 470 Shares of Glaukos Co. (NYSE:GKOS)

US Bancorp DE lifted its holdings in Glaukos Co. (NYSE:GKOS) by 8.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,099 shares of the medical instruments supplier’s stock after buying an additional 470 shares during the period. US Bancorp DE’s holdings in Glaukos were worth $914,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Amalgamated Bank lifted its position in Glaukos by 4.5% in the third quarter. Amalgamated Bank now owns 15,926 shares of the medical instruments supplier’s stock worth $2,075,000 after buying an additional 679 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in Glaukos by 15.8% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,051 shares of the medical instruments supplier’s stock valued at $527,000 after purchasing an additional 554 shares during the last quarter. Versor Investments LP purchased a new stake in Glaukos in the 3rd quarter worth about $457,000. WCM Investment Management LLC lifted its stake in Glaukos by 45.7% in the third quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier’s stock worth $12,721,000 after purchasing an additional 31,084 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Glaukos by 421.8% during the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock worth $10,320,000 after purchasing an additional 64,031 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Stock Up 0.9 %

Glaukos stock opened at $104.14 on Monday. The business’s 50-day simple moving average is $145.94 and its two-hundred day simple moving average is $138.90. The company has a market cap of $5.89 billion, a PE ratio of -36.29 and a beta of 0.99. Glaukos Co. has a fifty-two week low of $84.08 and a fifty-two week high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GKOS. UBS Group assumed coverage on Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective on the stock. Needham & Company LLC lifted their target price on Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research report on Monday, December 2nd. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their price target for the company from $140.00 to $200.00 in a report on Wednesday, February 19th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $163.25.

Insider Transactions at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 2,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,744 shares of company stock valued at $2,792,151 in the last 90 days. 6.40% of the stock is currently owned by company insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.